Latest News and Press Releases

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented...

– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy...

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy...

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

New York, USA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight Alpha-synuclein...

– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI...

Burlingame, Oct. 14, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Multiple System Atrophy (MSA) Market is estimated to value at US$ 148.1 Million in the year 2024, and is...

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May ...